VENTYX BIOSCIENCES INC (VTYX) Stock News

NASDAQ:VTYX - Nasdaq - US92332V1070 - Common Stock - Currency: USD

3.18 -0.02 (-0.62%)

After market: 3.15 -0.03 (-0.94%)

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VTYX Latest News, Press Relases and Analysis

All

Press Releases

a month ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Positive Top-Line Data from its Phase 2a Safety and Biomarker Trial Evaluating VTX3232 in Patients with Early-Stage Parkinson’s Disease

2 months ago - By: Benzinga - Mentions: CVM PRE HCTI TIL ...

12 Health Care Stocks Moving In Thursday's Intraday Session

2 months ago - By: Benzinga - Mentions: CVM HOOK HSDT LTRN ...

12 Health Care Stocks Moving In Thursday's Pre-Market Session

3 months ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Reports First Quarter 2025 Financial Results and Highlights Recent Corporate Progress

a year ago - By: InvestorPlace

VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q2 2024

4 months ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Expands SAB with Renowned NLRP3 Experts and Prominent Neurodegenerative and Cardiometabolic Disease Specialists

5 months ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Presentation of Data from the Phase 2 Trial of Allosteric TYK2 Inhibitor VTX958 in Crohn’s Disease at ECCO 2025

6 months ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

6 months ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Highlights 2025 Pipeline Strategy and Provides Clinical Updates on its NLRP3 Inhibitor Portfolio

8 months ago - By: Bragar Eagel & Squire

VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

a year ago - By: BusinessInsider

News Image

VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q1 2024

9 months ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

a year ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Initiation of Dosing in a Phase 2a Trial of VTX3232 in Patients with Early Parkinson’s Disease

a year ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Departure of Chief Financial Officer

a year ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in Two Upcoming Investor Conferences

a year ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Reports Second Quarter 2024 Financial Results and Highlights Recent Corporate Progress

a year ago - By: InvestorPlace

VTYX Stock Earnings: Ventyx Biosciences Beats EPS for Q1 2024

a year ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Announces Positive Preclinical Data for CNS-Penetrant NLRP3 Inhibitor VTX3232 Demonstrating Reversal of Obesity and Improvements in Cardiometabolic and Inflammatory Markers

a year ago - By: Bragar Eagel & Squire

VENTYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Ventyx Biosciences, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

a year ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences to Participate in Three Upcoming Investor Conferences

a year ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences Reports First Quarter 2024 Financial Results and Highlights Recent Corporate Progress

a year ago - By: Ventyx Biosciences, Inc.

Ventyx Biosciences to Report First Quarter 2024 Financial Results on May 9, 2024

a year ago - By: THE ROSEN LAW FIRM, P. A.

VTYX DEADLINE TODAY: ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Ventyx Biosciences, Inc. Investors to Secure Counsel Before Important April 30 Deadline in Securities Class Action - VTYX